Evidence map›Paper›PMID 39842922›Full record

ArticleBMJ open2025

Trends in certifications of overall vision impairment and that due to diabetic retinopathy/maculopathy in England and Wales, 2009/2010 to 2019/2020: a retrospective database analysis.

R L Thomas, Rebecca John, Catey Bunce, Wen Xing, Antra Zekite, Declan Flanagan, Gwyn Samuel Williams, Rhianon Reynolds, David Owens

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

R L ThomasDiabetes Resaerch Unit, Cymru, Swansea University, Swansea, UK r.l.thomas@swansea.ac.uk.ORCID http://orcid.org/0000-0002-2970-6352
Rebecca JohnNHS Wales Shared Services Partnership, Cardiff, UK.
Catey BunceRM CTU, Royal Marsden Hospital NHS Trust, London, UK.ORCID http://orcid.org/0000-0002-0935-3713
Wen XingMoorfields Eye Hospital City Road Campus, London, UK.
Antra ZekiteMoorfields Eye Hospital City Road Campus, London, UK.
Declan FlanaganMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Gwyn Samuel WilliamsOphthalmology, Singleton Hospital, Swansea, UK.
Rhianon ReynoldsSchool of Optometry and Vision Science, Cardiff University College of Biomedical and Life Sciences, Cardiff, UK.
David OwensDiabetes Research Group, Swansea University, Swansea, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to report the trends in the certification of both sight impairment (SI) and severe sight impairment (SSI) in England and Wales during the period of 2010 to 2020, prior to the COVID-19 pandemic. The focus is on diabetic retinopathy/maculopathy as the key causative factor.

designRetrospective database analysis.

settingEngland and Wales.

participantsIndividuals certified as SI or SSI. OUTCOME MEASURES: Trends in certification of vision impairment in England and Wales due to any cause, with specific attention to diabetic retinopathy.

methodsCertifications of vision impairment made by ophthalmologists in England and Wales were recorded and copies were sent to Moorfields Eye Hospital for epidemiological analysis. All certificates completed in England and Wales over an 11-year period, from April 2009 to March 2020, were queried and analysed on an annual basis. This analysis included all causes, and where both the main cause was diabetic eye disease or where diabetic eye disease was a contributory cause among multiple pathologies. Poisson regression was employed to analyse changes in trends over time for certifications of vision impairment.

resultsIn England, from 2010 to 2020, there was a small but significant reduction (p<0.001) in the overall rate of certifications for SI and SSI due to any cause, from 43.4 certifications per 100 000 people to 41.7 per 100 000 people. Conversely, in Wales, an initial decline was observed, with a decrease from 50.6 to 40.1 per 100 000 people from 2009/2010 to 2014/2015, respectively. This rate subsequently increased to 51.8 per 100 000 by 2019/2020; however, this was not statistically significant (p=0.087). Individuals in Wales had a 9% higher certification rate compared with those in England (1.09 (95% CI 1.07, 1.10)). For diabetic retinopathy, certifications in England significantly decreased from 72.8 to 41.3 per 100 000 people over the study period; in Wales, the certification rate initially declined from 82.3 to 47.1 per 100 000 by 2016/2017 before increasing to 55.5 per 100 000 in 2019/2020. Despite this fluctuation, there was a significant decrease in certifications due to diabetic retinopathy in Wales during the study period.

conclusionsThe findings underscore the importance of understanding regional variations in certification rates, particularly in the context of diabetic retinopathy. Despite fluctuations in Wales, the overall reduction in certifications due to diabetic retinopathy in both regions suggests a critical need for ongoing public health initiatives aimed at preventing vision impairment linked to diabetes. However, to provide a true reflection of the burden of vision impairment and its various causes, ensuring that all eligible people are certified is a prerequisite. Continuing attempts to limit the incidence of vision impairment due to diabetic retinopathy remain a priority.

Indexed as

CertificationDiabetic RetinopathyVision DisordersAdultAgedCOVID-19Databases, FactualEnglandFemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2WalesDIABETES & ENDOCRINOLOGYDiabetic retinopathyOPHTHALMOLOGY

Identifiers

PMID39842922
PMCPMC11758692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.